Talk:Glembatumumab vedotin

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Glembatumumab vedotin.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Dec 2012 poster of EMERGE final results

The EMERGE study shows the results presented in Dec 2012. Its conclusions are :

"EMERGE results consistent with previous study in similar population
* CDX-011 well-tolerated
 ‒ Less hematologic toxicity but more rash and neuropathy than Investigator’s Choice (IC)
* Promising activity in triple-negative breast cancer (TNBC), where treatment options are limited
 ‒ CDX-011 response rate of 19% in TNBC compared to 0% for IC
* Significant tumor expression of GPNMB associated with greater activity
 ‒ CDX-011 response rate of 32% compared to 13% for IC
 ‒ Stromal expression of GPNMB did not appear to correlate with outcome.
 ‒ High GPNMB expression in 41% of patients with TNBC
 ‒ CDX-011 response rate of 33% and doubling of PFS (p=0.008) and OS (p=0.003)
* A registrational study is being planned."

Could mention PFS etc in main article. - Rod57 (talk) 00:46, 4 February 2013 (UTC)[reply]